353 related articles for article (PubMed ID: 9865827)
21. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
22. Pathological analyses of early recurrence and malignant transformation in meningiomas.
Arai H; Beppu T; Wada T; Yoshida Y; Kubo Y; Suzuki M; Ogawa A
Brain Tumor Pathol; 1998; 15(1):37-40. PubMed ID: 9879462
[TBL] [Abstract][Full Text] [Related]
23. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods.
Nakasu S; Li DH; Okabe H; Nakajima M; Matsuda M
Am J Surg Pathol; 2001 Apr; 25(4):472-8. PubMed ID: 11257621
[TBL] [Abstract][Full Text] [Related]
24. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.
Wolfsberger S; Doostkam S; Boecher-Schwarz HG; Roessler K; van Trotsenburg M; Hainfellner JA; Knosp E
Neurosurg Rev; 2004 Oct; 27(4):238-45. PubMed ID: 15168138
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases.
Machen SK; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1511-6. PubMed ID: 9865840
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
Prayson RA
Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
30. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
[TBL] [Abstract][Full Text] [Related]
31. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
[TBL] [Abstract][Full Text] [Related]
32. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
[TBL] [Abstract][Full Text] [Related]
33. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas.
Langford LA; Cooksley CS; DeMonte F
Hum Pathol; 1996 Apr; 27(4):350-4. PubMed ID: 8617477
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
36. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas.
Konstantinidou AE; Korkolopoulou P; Kavantzas N; Mahera H; Thymara I; Kotsiakis X; Perdiki M; Patsouris E; Davaris P
Histol Histopathol; 2003 Jan; 18(1):67-74. PubMed ID: 12507285
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
[TBL] [Abstract][Full Text] [Related]
38. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas.
Antinheimo J; Haapasalo H; Haltia M; Tatagiba M; Thomas S; Brandis A; Sainio M; Carpen O; Samii M; Jääskeläinen J
J Neurosurg; 1997 Oct; 87(4):610-4. PubMed ID: 9322850
[TBL] [Abstract][Full Text] [Related]
39. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of Ki-67 Labeling Index and Postoperative Radiotherapy in WHO Grade II Meningioma.
Choi Y; Lim DH; Yu JI; Jo K; Nam DH; Seol HJ; Lee JI; Kong DS; Suh YL; Nam H
Am J Clin Oncol; 2018 Jan; 41(1):18-23. PubMed ID: 26270441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
